EVA-GLOBAL is an open entity aiming at developing synergies and complementary capabilities
The best way to get viral material within the Scientific Community. Browse our viruses and derived products from the EVAg Portal.
EVAg is a non profit organisation that mobilises a global network with expertise in virology to collect amplify characterise standardise authenticate distribute track viruses and derived products.
A unique biological resource in the field of virology, readily available online. Users may benefit from special funding to access to products of interest, do not hesitate to apply.
A network of laboratories
An international group of 25 laboratories, including 16 EU member state institutions and 9 non-EU institutions, that represent an extensive range of virological disciplines.
An open entity aiming at developing synergies and complementary capabilities in such a way as to offer an improved access to researchers.
The quality of viruses and derived products is a key consideration when our products are to be made available. Improvements on quality process will be addressed during the project.
Preparedness and Response
EVAg generates and distributes globally diagnostic materials and protocols in the event of epidemiological emergencies.
Focused on the creation of new tools, techniques and concepts to develop the infrastructure and to provide easier and less expensive access to virological materials.
A user-friendly web Portal with a continuously increasing number of viruses and derived products. Start here.
– The European Commission –
– The European Commission –
– The European Commission –
Our Latest Tweets
CALL FOR CONTRIBUTION: COVID19 antiviral compounds test results https://t.co/IJHwWNJoOA We created this page to SHARE preclinical evaluation of molecules with antiviral potential against the SARS-CoV-2. !!Negative results are important too!! Submission details in link provided https://t.co/tUucpSrsgc
We are glad we could help and fulfill one of our missions: providing rapidly essential tools to help fight pandemics. https://t.co/EceyMkDw4A
***IMPORTANT*** FLI added to the EVAG catalogue a SARS-CoV-2 recombinant antigen for serological assays ! Order Here FREE OF CHARGE WORLDWIDE: https://t.co/2issU5wVtL Assay described here https://t.co/f05bx7FF27 by @florian_krammer ‘s team Please share. @Loeffler_News https://t.co/K8vDJfNhvl
@NakedCapsid On a more personal note : management team is based in Marseille, sunny South of France, v. nice group of people, living in an office that we call “the corridor”, where we host nice crêpe parties, and eat definately too much chocolate, while wishing we could foster cats there.
@NakedCapsid Hi guys, well, we’re a non-profit org, a EU research infrastructure, a biobank distributing viruses and derived products. For free, worldwide. Yes, 2000 viruses on our online catalogue. We’ve distributed 2200 covid related products in 80 countries in 3 months. Speak soon 😉
1 800 SARS_CoV2 related products distributed in 80 countries in three months. But other viruses and derived products too ! Browse our online catalogue here: https://t.co/KsYZvDcKFt https://t.co/AIgVlHvUiu
@EU_H2020 @EUScienceInnov @EU_Commission @EU_Health @JEPaquetEU So far, we have distributed 1800 SARS-CoV2 related products, to Scientists in 80 countries. You can order online with an easy streamlined procedure through our website: https://t.co/KsYZvDcKFt Speak to you soon !
Welcome to the Virosphere indeed. At EVAG, we carefully select and archive the ones judged important by our committee of experts. More than 2000 strains available in our online catalogue for YOU, scientists studying them and fighting against them. https://t.co/WEsPpPDmGV
Recently on EVAg
COVID19: antiviral compounds test results
This section is dedicated to preclinical evaluation of molecules with antiviral potential against the SARS-CoV-2. It may receive links to important pu. read more
Access and benefit sharing under the Convention on Biological Diversity and the Nagoya Protocol
The EVA-GLOBAL community supports fair and equitable benefit sharing as conceived in various United Nations frameworks. The consortium is actively imp. read more
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
What Users Say
Our lab detected first coastal Kenya COVID-19 positive cases using EVA primers. This has allowed aggressive contact tracing and case isolation. Now were are key contributors in diagnostics in the Kenya and obtaining more diagnostic kits will go a long way in supporting local and national COVID-19 response plan.
Charles N. KEMRI – Wellcome Trust
Thank you so much! The package already arrived – I am amazed. We have so much problems with the primers and probes – some did not work, some were contaminated. Your ones are the only ones which work perfectly in our hands now. With your delivery, we can go on and meanwhile try to test additional providers.
B. Head of virology Dpt. Institute of Virolgy in Europe
We at Luminex were sincerely appreciative of your willingness to work with us during the development of our xMAP® MultiFLEX™ Zika RNA Assay. The materials from EVAg supported our FDA submission, which is now authorized for emergency use.
Sarah M. Dunlap, PhD Director, Clinical Operations – Luminex Corporation
We received high quality products at no cost. It helped us a lot in achieving our project. Thank you!
John User R & D – Laboratory
EVAg is a non profit organisation with expertise in virology to amplify, characterise, standardise, authenticate, distribute and track viruses and derived products.